GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PolyPeptide Group AG (XSWX:PPGN) » Definitions » EV-to-FCF

PolyPeptide Group AG (XSWX:PPGN) EV-to-FCF : -50.99 (As of May. 17, 2024)


View and export this data going back to 2021. Start your Free Trial

What is PolyPeptide Group AG EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, PolyPeptide Group AG's Enterprise Value is CHF1,105.6 Mil. PolyPeptide Group AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-21.7 Mil. Therefore, PolyPeptide Group AG's EV-to-FCF for today is -50.99.

The historical rank and industry rank for PolyPeptide Group AG's EV-to-FCF or its related term are showing as below:

XSWX:PPGN' s EV-to-FCF Range Over the Past 10 Years
Min: -201.94   Med: -11.36   Max: 623.73
Current: -49.55

During the past 6 years, the highest EV-to-FCF of PolyPeptide Group AG was 623.73. The lowest was -201.94. And the median was -11.36.

XSWX:PPGN's EV-to-FCF is ranked worse than
100% of 521 companies
in the Drug Manufacturers industry
Industry Median: 24.13 vs XSWX:PPGN: -49.55

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-17), PolyPeptide Group AG's stock price is CHF33.00. PolyPeptide Group AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-1.505. Therefore, PolyPeptide Group AG's PE Ratio for today is At Loss.


PolyPeptide Group AG EV-to-FCF Historical Data

The historical data trend for PolyPeptide Group AG's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PolyPeptide Group AG EV-to-FCF Chart

PolyPeptide Group AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial - - -208.28 -11.30 -31.14

PolyPeptide Group AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only -208.28 - -11.30 - -31.14

Competitive Comparison of PolyPeptide Group AG's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, PolyPeptide Group AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PolyPeptide Group AG's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PolyPeptide Group AG's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where PolyPeptide Group AG's EV-to-FCF falls into.



PolyPeptide Group AG EV-to-FCF Calculation

PolyPeptide Group AG's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1105.604/-21.681
=-50.99

PolyPeptide Group AG's current Enterprise Value is CHF1,105.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PolyPeptide Group AG's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-21.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PolyPeptide Group AG  (XSWX:PPGN) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

PolyPeptide Group AG's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=33.00/-1.505
=At Loss

PolyPeptide Group AG's share price for today is CHF33.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PolyPeptide Group AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-1.505.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


PolyPeptide Group AG EV-to-FCF Related Terms

Thank you for viewing the detailed overview of PolyPeptide Group AG's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


PolyPeptide Group AG (XSWX:PPGN) Business Description

Traded in Other Exchanges
Address
Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives a majority of its revenue from Europe and Asia.

PolyPeptide Group AG (XSWX:PPGN) Headlines

No Headlines